Yondelis must be given under the supervision of a doctor who is experienced in the use of chemotherapy (medicines to treat cancer). It should only be used by qualified oncologists (cancer specialists) or other health professionals who are specialised in …

Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in …

… as a clinical trial monotherapy has … drug appears to have utility in the relapsed ovarian cancer … trials.” Notably, in October 2015, the FDA approved trabectedin for the treatment … trabectedin is $2.1 billion, and sarcoma still represents an unmet medical …

… combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types … trials.” The primary outcome measures for the Phase 1 SB101 trial … biotechnology company with a proprietary platform for developing targeted biologic drugs …

… ESMO Sarcoma and Rare Cancers Annual Congress.1 The … press-announcements/fda-approves-first-drug-show-survival-benefit- … U.S. FDA approves Yondelis (trabectedin) for the treatment of patients … sarcoma. News release. Janssen Biotech, Inc. October 23, 2015 …

… cancer, relapsed and refractory multiple myeloma. The generic drug, Trabectedin Accord (trabectedin … brings disease-modifying treatment to all cystic … ). Ixchiq’s (chikungunya vaccine (live)) indication was … the Committee for Medicinal Products for Human …

… of the trials and these trials were underpowered … agents (cisplatin, etoposide, trabectedin, topotecan) is the loss … trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer … evidence in ovarian cancer. Drug Resist Updat Rev …

… generic medicine, Trabectedin Accord (trabectedin), received a positive opinion for the treatment of … indication of the chikungunya vaccine Ixchiq (chikungunya vaccine (live)) to … a medicine intended for the treatment of neuroblastoma, a rare cancer that …

… authorisation for the medicinal product Trabectedin Accord, intended for the treatment of advanced … division. By doing so, trabectedin prevents cancer cells from growing and causes …

… Accord Healthcare’s generic drug trabectedin, which has been … relapsed platinum-sensitive ovarian cancer. As for proposed … currently lacks any approved treatment options, Novartis said Friday … update. Plus, Spanish biotech HIPRA withdrew the application …